Jacobs Levy Equity Management, Inc Macrogenics Inc Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 815,865 shares of MGNX stock, worth $1.26 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
815,865
Previous 1,004,798
18.8%
Holding current value
$1.26 Million
Previous $1.22 Million
14.07%
% of portfolio
0.01%
Previous 0.01%
Shares
27 transactions
Others Institutions Holding MGNX
# of Institutions
112Shares Held
50MCall Options Held
65.5KPut Options Held
93.9K-
Bellevue Group Ag Kuesnacht, V89.92MShares$15.3 Million0.36% of portfolio
-
Armistice Capital, LLC New York, NY5.96MShares$9.18 Million0.16% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$8.32 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$6.51 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.18MShares$4.89 Million0.23% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $94.6M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...